Proacta Incorporated
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Proacta Incorporated
US green light for clinical testing of Proacta's reversible MKI inhibitor
The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.
ApniCure: Unmasking Sleep Therapy With An Alternative To CPAP
Sleep apnea is now widely recognized as an underlying factor for major CV diseases and metabolic disorders, making it a huge market opportunity. ApniCure hopes that by avoiding the CPAP masks that patients hate while using the differential pressure therapy that doctors and payors like, it can unlock this potential blockbuster market.
Medical Device Deals Update, June/July 2012
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Deals Shaping The Medical Industry, June 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice